147 related articles for article (PubMed ID: 2031196)
41. Phase II study of Lonidamine in cancer patients.
Band PR; Deschamps M; Besner JG; Leclaire R; Gervais P; De Sanctis A
Oncology; 1984; 41 Suppl 1():66-8. PubMed ID: 6717898
[TBL] [Abstract][Full Text] [Related]
42. Phase II study of lonidamine in inoperable non-small-cell lung cancer.
Kokron O; Maca S; Scheiner W; De Gregorio M; Ciottoli GB
Oncology; 1984; 41 Suppl 1():86-9. PubMed ID: 6717902
[TBL] [Abstract][Full Text] [Related]
43. Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study.
Marshall ME; Mendelsohn L; Butler K; Riley L; Cantrell J; Wiseman C; Taylor R; Macdonald JS
J Clin Oncol; 1987 Jun; 5(6):862-6. PubMed ID: 3585442
[TBL] [Abstract][Full Text] [Related]
44. Phase II evaluation of Lonidamine in patients with advanced malignancy.
Evans WK; Shepherd FA; Mullis B
Oncology; 1984; 41 Suppl 1():69-77. PubMed ID: 6717899
[TBL] [Abstract][Full Text] [Related]
45. Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifen.
Papac RJ; Keohane MF
Eur J Cancer; 1993; 29A(7):997-9. PubMed ID: 8499154
[TBL] [Abstract][Full Text] [Related]
46. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Amadori D; Frassineti GL; De Matteis A; Mustacchi G; Santoro A; Cariello S; Ferrari M; Nascimben O; Nanni O; Lombardi A; Scarpi E; Zoli W
Breast Cancer Res Treat; 1998 Jun; 49(3):209-17. PubMed ID: 9776504
[TBL] [Abstract][Full Text] [Related]
47. Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1.
Scagliotti GV; Gozzelino F; Albera C; Pescetti G
Chemotherapy; 1989; 35(1):64-8. PubMed ID: 2541978
[TBL] [Abstract][Full Text] [Related]
48. The combined use of radiation therapy and lonidamine in the treatment of brain metastases.
DeAngelis LM; Currie VE; Kim JH; Krol G; O'Hehir MA; Farag FM; Young CW; Posner JB
J Neurooncol; 1989 Sep; 7(3):241-7. PubMed ID: 2677257
[TBL] [Abstract][Full Text] [Related]
49. Lonidamine in advanced colorectal cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
Passalacqua R; Bisagni G; Bertusi M; Donati D; Buzzi F; Di Costanzo F; Basurto C; Gori S
Tumori; 1989 Jun; 75(3):277-9. PubMed ID: 2672481
[TBL] [Abstract][Full Text] [Related]
50. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study.
Winquist E; Knox J; Ayoub JP; Wood L; Wainman N; Reid GK; Pearce L; Shah A; Eisenhauer E
Invest New Drugs; 2006 Mar; 24(2):159-67. PubMed ID: 16502349
[TBL] [Abstract][Full Text] [Related]
51. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.
Schöffski P; Guillem V; Garcia M; Rivera F; Tabernero J; Cullell M; Lopez-Martin JA; Pollard P; Dumez H; del Muro XG; Paz-Ares L
Mar Drugs; 2009; 7(1):57-70. PubMed ID: 19370171
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma.
Piot G; Droz JP; Theodore C; Ghosn M; Rouëssé J; Amiel JL
Oncology; 1988; 45(5):371-2. PubMed ID: 3412745
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).
Stephens RL; Goodman P; Crawford ED; Spicer CF; Lowe BA; Ahmann FR; Chapman R; Natale RB
Invest New Drugs; 1990; 8 Suppl 1():S69-71. PubMed ID: 2143177
[TBL] [Abstract][Full Text] [Related]
54. Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.
Young CW; Currie VE; Kim JH; O'Hehir MA; Farag FM; Kinahan JE
Oncology; 1984; 41 Suppl 1():60-5. PubMed ID: 6717897
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma.
Dexeus FH; Logothetis CJ; Sella A; Fitz K; Amato R; Reuben JM; Dozier N
J Clin Oncol; 1990 Feb; 8(2):325-9. PubMed ID: 2137163
[TBL] [Abstract][Full Text] [Related]
56. Phase II trial of LY 186641 in advanced renal cancer.
Mahjoubi M; Kattan J; Bonnay M; Schmitt H; Droz JP
Invest New Drugs; 1993 Nov; 11(4):323-8. PubMed ID: 7726992
[TBL] [Abstract][Full Text] [Related]
57. Early observations on the administration of Lonidamine in cancer patients.
Barduagni A; Barduagni M; Di Lauro L; Nardi M; Gallo Curcio C; Tonachella R; Ciottoli GB; Delle Chiaie S
Oncology; 1984; 41 Suppl 1():78-81. PubMed ID: 6717900
[TBL] [Abstract][Full Text] [Related]
58. The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Newell DR; Mansi J; Hardy J; Button D; Jenns K; Smith IE; Picollo R; Catanese B
Semin Oncol; 1991 Apr; 18(2 Suppl 4):11-7. PubMed ID: 2031191
[TBL] [Abstract][Full Text] [Related]
59. Tamoxifen treatment of advanced endometrial carcinoma. A phase II study.
Hald I; Salimtschik M; Mouridsen HT
Eur J Gynaecol Oncol; 1983; 4(2):83-7. PubMed ID: 6873094
[TBL] [Abstract][Full Text] [Related]
60. Phase II study of lonidamine in non-small cell lung cancer: final report.
Kokron O; Maca S; De Gregorio M; Ciottoli GB
Br J Cancer; 1990 Feb; 61(2):316-8. PubMed ID: 2155644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
